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Simple Summary: Every patient responds to radiotherapy in individual manner. Some suffer severe
side-effects because of normal tissue toxicity. Their radiosensitivity can be caused by inability of
DNA repair system to fix radiation-induced damage. The γ-H2AX assay can detect such deficiency in
untransformed primary cells (e.g., peripheral blood mononuclear cells, PBMC), over a period of only
hours post ex-vivo irradiation. Earlier we have shown that the level and kinetics of decline (repair) of
radiation-induced DNA damage detected by the assay is a measure of the cellular radiosensitivity.
In this study, we applied the γ-H2AX assay to judge the radiosensitivity of lung cancer radiotherapy
patients as normal or abnormal, based on kinetics of DNA damage repair. Considering the potential
of the assay as a clinical biodosimeter, we also monitored DNA damage in serial samples of PBMC
during the course of radiotherapy. This study opens an opportunity to monitor individual response
to radiotherapy treatment.
Abstract: Thoracic radiotherapy (RT) is required for the curative management of inoperable lung
cancer, however, treatment delivery is limited by normal tissue toxicity. Prior studies suggest that
using radiation-induced DNA damage response (DDR) in peripheral blood mononuclear cells (PBMC)
has potential to predict RT-associated toxicities. We collected PBMC from 38 patients enrolled on
a prospective clinical trial who received definitive fractionated RT for non-small cell lung cancer.
DDR was measured by automated counting of nuclear γ-H2AX foci in immunofluorescence images.
Analysis of samples collected before, during and after RT demonstrated the induction of DNA damage
in PBMC collected shortly after RT commenced, however, this damage repaired later. Radiation
dose to the tumour and lung contributed to the in vivo induction of γ-H2AX foci. Aliquots of PBMC
collected before treatment were also irradiated ex vivo, and γ-H2AX kinetics were analyzed. A trend
for increasing of fraction of irreparable DNA damage in patients with higher toxicity grades was
revealed. Slow DNA repair in three patients was associated with a combined dysphagia/cough
toxicity and was confirmed by elevated in vivo RT-generated irreparable DNA damage. These results
Cancers 2020, 12, 2517; doi:10.3390/cancers12092517 www.mdpi.com/journal/cancers
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
9
4
1
3
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Cancers 2020, 12, 2517 2 of 20
warrant inclusion of an assessment of DDR in PBMC in a panel of predictive biomarkers that would
identify patients at a higher risk of toxicity.
Keywords: non-small cell lung cancer; radiation therapy; DNA damage repair
1. Introduction
Radiotherapy (RT) is included in the treatment of half of all patients with cancer. This treatment is
commonly used as the primary curative modality in a number of different cancers including carcinomas
of the lung, head and neck, cervix and prostate. Across all cancer types, the inclusion of RT is associated
with improvements in 5-year local control and overall survival (OS) of an estimated 23% and 6%,
respectively [1]. In some tumour types, such as unresectable locally advanced lung cancer, RT is the
only available primary curative modality available. The efficacy of RT in cancer treatment is steadily
improving, largely driven by rapid developments in technology, which aim to maximize the dose to the
tumour while minimizing the dose to normal tissues. The management of cancer is a rapidly evolving
landscape with successes including the advent of immunotherapy, targeted therapies, improvements
in chemotherapy and surgical oncology. This has resulted in significant improvements in survival
(in the United States, there are now >14 million cancer survivors; ~4% of the population) [2,3], such that
toxicity remains one of the main concerns when deciding on a treatment regimen.
RT has a prominent role in the treatment of lung cancer. In the curative setting, it is the standard
of care in patients with inoperable localized disease and those with mediastinal nodal involvement.
In stage III non-small cell lung cancer (NSCLC), RT is the most commonly used primary local
treatment. In this cohort the 5-year survival rates are still modest, reported at 32% in a modern RT
trial [4]. The recent addition of adjuvant systemic immunotherapy is expected to significantly increase
long-term survival, with an ongoing clinical trial reporting an improvement in 2-year OS rate (66% with
immunotherapy vs. 56% chemo-RT alone) [5].
Despite advances in technology, RT continues to pose some risk of both acute and late toxicity.
Thoracic RT is associated with a risk of developing acute pneumonitis and chronic lung fibrosis [6].
Symptomatic pneumonitis occurs in a third of patients treated with curative intent lung RT, with fatal
pneumonitis occurring in 2% of these patients. The prescribed radiation dose and the mean lung dose
are the strongest treatment factors associated with pneumonitis [6]. Other factors that increase this risk
further include the use of concurrent chemotherapy, the presence of interstitial lung disease and age.
There is also a small population of patients who experience significant, even fatal toxicity without any
significant risk factors and despite appropriate RT plans. It has been hypothesized that this group of
patients may have inherent biological factors underlying their radiation sensitivity (RS), and that if
detected before or early in treatment, their plans could be adapted to reduce the risk of toxicity [7].
We conducted a clinical trial that explored gallium-68 ventilation/perfusion (V/Q) positron
emission tomography (PET) as an imaging marker of pulmonary toxicity [8]. The overall aim of the
trial was to understand the fundamental effects of radiation on pulmonary physiology, to better predict
radiation toxicity and to work towards future reductions in radiation toxicity by avoiding irradiation
of functionally critical segments of lung. The immune response and accumulated unrepaired systemic
DNA damage have been proposed to underlie RT-induced toxicities [9–11], and therefore, the associated
molecules provide a source of potential predictive biomarkers. Since the relevant tissue for pulmonary
toxicity, healthy lung, is inaccessible without unacceptable clinical risk, we restricted our search for
predictive biomarkers to minimally invasive blood sampling, concentrating on plasma inflammatory
cytokine response to treatment (a manuscript in preparation) and radiation-induced DNA damage
response (DDR) in peripheral blood mononuclear cells (PBMC). The latter is a subject of this report.
The discovery in 1998 of histone H2AX phosphorylation (forming γ-H2AX) in response to
DNA double-strand breaks (DSB) induction advanced the field of DNA damage and repair [12].
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The exquisite sensitivity (a single DSB in a nucleus can be visualized within a nucleus) and speed of
DNA damage detection (the signal peaks minutes after the DSB formation) have made the γ-H2AX
assay an indispensable tool for measuring DNA damage in situ [13]. The assay has utility across
biodosimetry, relative biological effectiveness of novel RT modalities including radionuclide therapy,
as well as chemotherapy. One of these exploited the systemic DNA damage propagation in NSCLC RT
patients [14]; this study suggested the potential of the accumulated unrepaired DNA damage to predict
RT-associated toxicities. Further, in a retrospective study, the assay revealed that compromised DDR
is associated with extreme RS [15,16]. Finally, the assay has been used as a biodosimeter in clinical
studies [17,18] and has been exploited for clinical trials, e.g., [19,20].
In this study, we followed the γ-H2AX foci formation and disappearance in PBMC collected prior
to, during and post-RT treatment in NSCLC patients recruited for the GalliPET VQ-RT prospective
clinical trial. We describe a common trend and individual variations of DDR to the treatment.
We searched for associations of the observed DDR with various types of RT-related toxicity and the
tumour response.
2. Results
Experimental scheme of the study is presented in Figure 1. We collected blood samples before
commencement of RT (“baseline”), at 1 h post first RT fraction, 24 h post first RT fraction before the
2nd RT session, 4 weeks into RT and 3 months after the end of RT. The study consists of two parts:
(1) in vivo study, where PBMC were not exposed to ex vivo irradiation, thus detected γ-H2AX foci per
cell (fpc) that were induced either by endogenous factors or by RT treatment for NSCLC and (2) ex vivo
study, where PBMC collected prior to commencement of RT were exposed ex vivo to 2-Gy irradiation
that induced the γ-H2AX response.
Figure 1. Experimental scheme of the study. Patients with non-small cell lung cancer (NSCLC) were
recruited for the GalliPET VQ-RT clinical trial. The γ-H2AX biomarker study was a biological part
of the clinical trial. Venous blood was collected at the indicated time points before, during and after
radiotherapy (RT) treatment and processed as described in Section 4. Peripheral blood mononuclear
cells (PBMC) collected at all time points were not exposed to ex vivo irradiation (in vivo γ-H2AX
study), except an aliquot of a baseline PBMC sample that was subsequently ex vivo irradiated (ex vivo
γ-H2AX study). Ventilation/perfusion (V/Q) positron emission tomography (PET) prior to treatment
and post-treatment enabled assessment of treatment toxicity and tumour progression.
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2.1. In Vivo Study: γ-H2AX Foci in PBMC that Were Not Exposed to Ex Vivo Irradiation
Isolated PBMC were fixed immediately after blood collection (and subsequently immunostained
for γ-H2AX) and, when it was logistically possible, also at 24 h post blood collection. Table 1
summarizes the statistics of fpc numbers for each group in PBMC that were fixed early: the arithmetic
mean value, standard deviation, number of samples, and p-values for the comparison of each group
with the baseline. Table S1 shows the same values for PBMC that were fixed 24 h after blood collection.
The 4-week time point was a mixed group. Due to treatment logistics, i.e., timing of patients’ RT and
chemotherapy schedules, some blood samples were collected after delivery of the RT session (at 1–6 h),
while some were collected before the session. The results for each of these two subgroups are shown
separately in Table 1.
Table 1. Statistics of γ-H2AX foci per cell (fpc) values in peripheral blood mononuclear cells (PBMC)
collected at different time points and fixed immediately after blood collection.
Time Points
of Blood Collection Baseline
1 H Post
First RT
24 H Post
First RT
4 Weeks †
(Sample Pre-RT)
4 Weeks †
(Sample Post-RT)
3 Months
Post-Final RT
Mean Value, fpc 1.11 3.24 1.26 1.57 2.39 1.09
Standard Deviation 0.37 0.68 0.57 0.50 0.91 0.52
Number of samples 43 38 38 18 16 29
p-value 1 relative to
baseline
<0.0001 * 0.130 0.0089 * <0.0001 * 0.688
1p-values are given for paired t-test. * Statistically significant. † Due to treatment logistics some samples taken at 4
weeks were collected before the RT session (pre-RT) and some were collected after (post-RT).
Figure 2A illustrates dynamics of γ-H2AX fpc in PBMC that were fixed immediately after blood
collection, for all time points and patients, and representative microscopy images are shown in
Figure 2B. There is a significant increase of mean foci numbers at two time points of blood collection,
approximately three fold at 1 h post first RT session (3.24 fpc) compared to the baseline value (1.11 fpc),
p < 0.0001, for both paired and unpaired t-test, and at 4 weeks in the RT, with more than two fold
increase in samples collected post-RT session (2.39 fpc, p < 0.0001 for both paired and unpaired t-test),
and some increase in samples collected pre-RT session (1.57 fpc, p = 0.0089, paired t-test). The substantial
increase of foci post-RT sessions is assumed to be related to the presence in the blood samples of cells
that had been in the irradiated volume during delivery of RT treatment [14], as described in details in
Text S1. This interpretation is consistent with the subsequent decrease of fpc in the same samples that
were fixed late, at 24 h post blood collection (Table S1), thus allowing time for foci elimination as a
result of γ-H2AX dephosphorylation, signifying ex vivo repair of radiation-induced DSB. A similar
decrease of fpc was observed in the samples collected at 24 h post first RT fraction (Table 1), ascribed to
in vivo repair.
The analysis of foci frequency distributions (Figure 2C) supports this interpretation.
The background foci form randomly, and their distribution follows Poisson statistics, as indicated by
high R-squared value of nonlinear regression analysis (0.975). If a subpopulation of cells is irradiated,
a two-component foci frequency distribution is expected. Indeed, at 1 h post first RT session, apart from
the higher mean foci number, the agreement of the experimental histogram with Poisson distribution is
weaker (R = 0.853), due to the presence of cells with a substantially higher foci numbers than expected
from the random distribution. A further analysis of foci frequency distributions is presented in the
first paragraph of Section 2.3.
2.2. Ex Vivo Study: Kinetics of γ-H2AX Foci in Baseline PBMC that Were Exposed to Ex Vivo Irradiation
Aliquots of PMBC from blood samples collected at baseline (before commencement of RT) were
irradiated ex vivo to a dose of 2 Gy 137Cs γ-rays, or 320 KeV X-rays, and fixed at serial time points (1, 3,
6 and 24 h). In Figure 3A,B regression analysis of post irradiation γ-H2AX foci kinetics averaged for
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the entire cohort is shown (Figure 3A), as well as representative examples of a large variation between
patients (Figure 3B).
Figure 2. γ-H2AX foci in PBMC not exposed to ex vivo irradiation. (A) γ-H2AX foci counts in PBMC
for all time points and patients (PBMC were fixed immediately after blood collection). Scatter plots of
γ-H2AX foci numbers from groups of samples obtained at different time points of radiotherapy (RT)
treatment. For data obtained from samples collected at 4 weeks into RT, two subgroups are shown,
samples obtained pre-RT session and post-RT session, as explained in the text. Each point represents
the arithmetic mean of foci numbers counted in images from an individual patient. Bars show the mean
values and standard deviations for each group. * Statistically significant. (B) Representative confocal
microscopy images of PBMC immunostained with anti-γ-H2AX antibody from patient GP39 at baseline
(top row), 1 h after the first RT session when PBMC were either fixed immediately after blood collection
(fixed early; middle row) and when PBMC were fixed 24 h after blood collection (fixed late; bottom
row). The left column shows green channel, γ-H2AX, and right column shows blue (DAPI) channel
(nuclei). Objects (nuclei) selected for the analysis are outlined in pink. Scale bar, 10 µm. (C) Averaged
γ-H2AX foci frequency distributions in PBMC collected at baseline (left panel) and 1 h post first RT
(right panel). Solid lines are the best fit Poisson distributions. Arithmetic mean values are 1.08 and 3.18,
best-fit Poisson average values 0.53 and 1.06 and R-squared values for the nonlinear regression are
0.975 and 0.853, for the baseline and 1-h groups, respectively.
We previously reported that two parameters derived from the nonlinear regression analysis
(curve fitting) of foci kinetics (Equation (4) from Section 4), as well as their combination, were associated
with extreme normal tissue toxicity in RT patients [15]. The two parameters reflect the fraction of DNA
damage, which is apparently irreparable, determined by extrapolation to infinite time, of the curve
fitted through the data points for each plot following the decay of damage with time (Q) and the rate of
repair as a fraction of fpc per hour (R). The Q and R are individual for each dataset (i.e., each patient);
the values reported here correspond to the statistically best fit curves through the experimental data.
The best predictor of extreme RS was the combination of these two values, the 2-D mapping onto R
and Q coordinates (“RS map”) [15]. The results of the foci kinetics analysis are summarized in Table S2,
and displayed in Figure 3C,D. Figure 3C shows scatter plots of Q and R values, and Figure 3D shows
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the RS map for all patients. The frequency distributions for both values (shown in Figure S1) pass the
normality tests (p > 0.1, Kolmogorov-Smirnov test), indicating that each data set is derived from a
single population without obvious outliers.
Figure 3. γ-H2AX foci kinetics following ex vivo irradiation of PBMC collected at baseline. PBMC
were collected prior to RT, exposed to 2 Gy-irradiation and fixed at serial time points. (A) Average
γ-H2AX foci kinetics for all patients. Data points and error bars represent the mean foci number across
all patients and the standard deviation. (B) Representative examples of a large variation of foci kinetics
between patients; with small Q (the fraction of irreparable DNA damage) and large R (the fraction of
fpc per hour) (GP48) and large Q and small R (GP29). The symbols represent experimental points, and
the lines are obtained as a result of nonlinear regression. Values of the best fit parameters Q and R are
0.225 ± 0.0624 and 0.199 ± 0.060, respectively, for GP29 and 0.077 ± 0.011 and 0.319 ± 0.018, respectively,
for GP48. (C) Scatter plots of Q and R values obtained from nonlinear regression of foci kinetics. Each
point on scatter diagrams represents an individual patient. Mean values ± standard deviations are
0.163 ± 0.046 and 0.254 ± 0.052 for Q and R values, respectively. (D) Q-R map (“RS map”) showing
values of the parameters in R and Q coordinates. Each point represents an individual patient, and
numerical values correspond to the patient numbers. The top left-hand region of the map corresponds
to compromised DNA repair.
To understand if DSB repair in ex vivo irradiated PBMC correlates with DSB repair in PBMC
exposed to RT in vivo, we studied a correlation between Q-values and the ratio of foci in PBMC
collected at 24 and 1 h post first RT (shown in Table S2). The lower ratio indicates better repair.
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We found a statistically significant correlation between these values (r = 0.487, p = 0.0035), as illustrated
in Figure 4. We also found a statistically significant correlation between fpc numbers in PBMC collected
at 24 h post first RT session and Q-values (r = 0.529, p = 0.001).
Figure 4. Correlation between Q-values and the ratio of background foci in PBMC collected at 24 and
1 h post first radiotherapy (RT) session. The 24/1 h ratios for all patients are presented in Table S2.
This ratio reflects the efficiency of in vivo repair of DNA damage induced in PBMC by RT treatment.
2.3. Correlation Studies with Treatment Conditions; PBMC that Were not Exposed to Ex Vivo Irradiation
We further deconvoluted γ-H2AX foci that originated from RT and background foci, by applying a
nonlinear regression analysis to foci frequency distributions (Equation (1) from Section 4). Nonirradiated
PBMC have random background foci that follow Poisson statistics (Equation (2) from Section 4).
Radiation-induced foci are generally random events as well, but foci induced in a fraction of PBMC that
were exposed while traveling through the irradiated thorax and receiving different doses, do not follow
Poisson statistics. For these cells, we used gamma-distribution (Equation (3) from Section 4). The best
fit values were obtained for the fraction of irradiated cells and the average number of radiation-induced
foci in these cells. The results of this analysis for each patient are presented in Table S3.
These values were used in the correlation analysis with planned treatment volume (PTV) and
mean lung dose (MLD). A weak association of the average fpc numbers with PTV (r = 0.235, p = 0.155)
was observed. A statistically significant correlation was found between the fraction of irradiated
PBMC and PTV (r = 0.417, p = 0.009). The product of the average radiation-induced fpc number and
the fraction of irradiated PBMC demonstrated the best correlation with PTV (r = 0.586, p = 0.0001).
This product equals to the excess foci number that is defined as a difference between mean fpc in
PBMC collected at 1 h post first RT fraction and at baseline. The results are summarized in Table 2 and
illustrated in Figure 5A.
Table 2. Pearson correlation of foci induction at 1 h post first radiotherapy (RT) with planned treatment
volume (PTV) and mean lung dose (MLD).
Parameter
PTV MLD Combined PTVand MLD
Correlation
Coefficient p-Value
Correlation
Coefficient p-Value
Correlation
Coefficient p-Value
Average per cell number of induced foci 0.235 0.155 0.234 0.158
Fraction of affected cells 0.417 0.010 0.274 0.0955
Average per cell number of excess foci 0.586 0.00011 0.437 0.00060 0.601 <0.0001
MLD 0.597 <0.0001
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Figure 5. Correlation of the excess foci number with planned treatment volume (PTV) and mean lung
dose (MLD). (A) PTV and (B) MLD correlation analysis for a group of patients with blood samples
collected at 1 h after first RT session. Each point represents the data for an individual patient. The
excess foci number is calculated as the product of the average radiation-induced fpc and the fraction
of irradiated cells from Table S3. The lines show the linear regression and 95% confidence intervals.
Correlation coefficient r = 0.586, p = 0.00011 for PTV and r = 0.437, p = 0.0006 for MLD.
We found a weaker association of the excess foci number with MLD (Table 2 and Figure 5B;
r = 0.437, p = 0.006). MLD correlated significantly with PTV (r = 0.597, p < 0.0001), thus these values
are interdependent. We also generated a combined PTV and MLD variable as a linear combination of
these values that provides the best fit for the excess foci number. The excess foci number correlated
with this combined variable better than with PTV or MLD (r = 0.601, p < 0.0001) indicating that the
dose to both tumour and lung contributes to the induction of foci (Table 2).
We also calculated the number of RT-induced foci by taking into account PTV and MLD,
as described in Text S1. Although, due to limited accurate information on blood flow in the thorax
and treatment duration, it is difficult to obtain a reliable prediction of the fraction of irradiated cells
and the average foci number, it is possible to establish the relationship between these values, using
average values for PTV (500 cm3) and MLD (0.486 Gy/fraction). The results are shown in Figure S2.
The average foci numbers obtained from experimental data (Table S3) correlated with calculated foci
numbers (r = 0.604, p < 0.01). The values were calculated as described in Text S1 using treatment
parameters for each patient, however, the calculated values underestimate the experimental values.
This analysis also indicates that irradiation of both tumour and lung contributes to the induction of
foci in PBMC to a similar extent, with average per irradiated cell doses of 33 and 49 mGy for tumour
and lung, respectively.
2.4. Correlation Studies with Treatment Outcomes; Baseline PBMC that Were Exposed to Ex Vivo Irradiation
We explored whether an association exists between the unrepairable component Q and repair
rate R values across 7 types of RT-induced acute toxicity using CTCAE criteria. The severity of each
type of toxicity was evaluated as a four-level grade score (0–3; there were no treatment-related CTCAE
grade 4 or 5 toxicities in the cohort). For each patient, we first calculated the combined toxicity grade
(the sum of grades for each type of toxicity, which varied from 3 to 11) and found a weak association of
this parameter with Q-values (r = 0.152, p = 0.36, Figure S3). Then, we applied the t-test to compare
Q-values in 3 subgroups of patients with different toxicity grades for each of the 7 types of toxicity.
These subgroups corresponded to toxicity grades 0, 1 and combined 2 and 3, since only 5 cases of grade
3 toxicity were observed. The results including average values for each subgroup and p-values for
comparison of grades 1 and 2 with grade 0 are summarised in Table 3. Scatter plots illustrating this
analysis are presented in Figure S4.
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Table 3. Summary of the statistics and comparison of Q- and R-values for subgroups of patients with
various metabolic response and normal tissue toxicity grades for seven types of toxicity.
Tumour
Response/Toxicity Grade N
Q-Values R-Values
Average SD p-Value Average SD p-Value
Tumour response
CMR 1 12 0.155 0.048 0.246 0.048
PMR 2 10 0.159 0.049 0.827 0.251 0.061 0.821
PMD 3 7 0.167 0.048 0.600 0.277 0.039 0.146
Dyspnoea
0 7 0.161 0.044 0.226 0.050
1 18 0.175 0.043 0.488 0.265 0.048 0.110
2 14 0.149 0.050 0.586 0.252 0.055 0.299
Cough
0 3 0.140 0.018 0.230 0.035
1 27 0.162 0.048 0.155 0.256 0.058 0.327
2 9 0.174 0.048 0.098 0.253 0.036 0.383
Pneumonitis
0 20 0.168 0.042 0.267 0.055
1 7 0.140 0.039 0.135 0.227 0.051 0.109
2 12 0.168 0.056 0.998 0.247 0.041 0.265
Dermatitis
0 9 0.170 0.044 0.210 0.032
1 22 0.162 0.047 0.661 0.270 0.049 0.001
2 9 0.141 0.071 0.314 0.228 0.098 0.630
Fatigue
0 4 0.171 0.046 0.224 0.057
1 27 0.156 0.047 0.589 0.268 0.046 0.218
2 7 0.189 0.042 0.551 0.229 0.040 0.878
Nausea
0 30 0.157 0.048 0.249 0.053
1 7 0.186 0.040 0.131 0.269 0.046 0.348
2 2 0.166 0.016 0.587 0.267 0.066 0.768
Dysphagia
0 12 0.135 0.045 0.253 0.069
1 13 0.168 0.037 0.061 0.244 0.044 0.690
2 14 0.182 0.047 0.016 0.263 0.042 0.697
Cough +
dysphagia
0-1 11 0.138 0.046 0.257 0.072
2 10 0.161 0.044 0.264 0.227 0.038 0.251
3 15 0.170 0.042 0.083 0.239 0.098 0.583
4 3 0.222 0.010 0.00011 0.242 0.030 0.598
1 CMR = complete metabolic response; 2 PMR = partial metabolic response; 3 PMD = progressive metabolic disease.
For two types of toxicity, dysphagia and cough, a trend for increasing Q-values in subgroups with
higher toxicity grades was observed. For the increase of Q-values for grade 1 and 2 cough, p-values
were 0.155 and 0.098, respectively; for grade 1 dysphagia, p = 0.061 and statistically significant for
grade 2 dysphagia (p = 0.016). Scatter plots illustrating this trend are presented in Figure 6A,B.
To look further into the relationship between Q-values and the severity of dysphagia and cough,
we calculated the combined criterion as a sum of dysphagia and cough toxicity grades and analyzed
four subgroups (grades 0–1, 2, 3 and 4). A similar trend for increasing Q-values was observed for this
combined criterion with a statistically significant increase in grade 4 compared to grade 0–1 (p < 0.001)
(Figure 6C). A positive correlation was found between Q and the combined dysphagia/cough toxicity
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grade (r = 0.412, p = 0.010, Figure S3). These results indicate that dysphagia and cough are not
independent toxicities.
Figure 6. Comparison of Q-values in subgroups of patients with acute normal tissue toxicity—Dysphagia
and cough. Diagrams show scatter plots of Q-values in subgroups of patients with: (A) grades 0, 1 and
2 of dysphagia; (B) grades 0, 1 and 2 of cough; (C) combined grades of dysphagia and cough. Mean
Q-values and their standard deviations for each subgroup are presented in Table 3.
The analysis of the combined dysphagia/cough toxicity identified three patients with combined
score 4 (GP53, GP62 and GP63) that have Q-values at the highest end of the range (0.21–0.23).
Interestingly, for patients GP53 and GP62, the toxicity grade 2 was observed for 5 out of 7 toxicity
criteria, including radiation-induced pneumonitis, and only for these patients, the overall combined
toxicity grade reached 11. These patients map to the higher RS zone on the 2-D RS map (Figure 3D)
and correspond to higher ratios of mean foci number in samples collected at 24 h vs. 1 h post first RT,
reflecting compromised efficiency of the repair of RT-induced foci. This ratio is higher for GP53, GP62
and GP63 (0.69, 0.45 and 0.56, respectively) than the average ratio of 0.41 (Table S2). On a retrospective
chart review for the presence of late toxicity (median follow up time 2 years), all three of these patients
had unusual pulmonary toxicity, persistent grade 2 symptoms of cough and/or shortness of breath,
and ultimately required ongoing medical interventions. All patients also demonstrated a complete
metabolic response at 3 months post-treatment. At the time of last follow up, all patients were alive
and only one patient developed a recurrence, which was able to be salvaged with curative intent.
No correlation was found between normal toxicity grades and values of repair rate R (Figure S5),
as well as between metabolic response and both Q and R values, as evidenced from the data presented
in Table 4.
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Table 4. Patient characteristics.
Patient
ID Age Gender Pathology Stage
PTV
(cm3) MLD RT/CRT
4 Weeks Beforeore
or After RT
PET
Response
Dyspnoea
Grade
Cough
Grade
Pneumonitis
Grade
Dermatitis
Grade
Fatigue
Grade
Nausea
Grade
Dysphagia
Grade
GP26 59 M SCC N/A 11.69 N/A 1 1 0 0 0 0 0
GP27 67 M NSCLC T2N2M0 360 19.79 CRT: ca/pa Before CMR 0 1 0 2 1 1 2
GP28 69 M AC T2N2M0 453 15.73 CRT: ca/pa N/A 0 1 0 0 0 0 2
GP29 49 M AC T4N0M0 387 8.00 CRT: cis/et Before N/A 1 1 0 0 2 0 1
GP30 48 F AC T3N3M0 493 8.75 CRT: cis/et After PMR 0 0 1 2 1 0 2
GP31 63 M SCC T3N2M1b 1081 20.45 CRT: ca/pa After PMD 1 2 2 1 0 0 1
GP32 64 M SCC T1aN1M1b 184 14.79 CRT: ca/pa After PMR 1 1 2 2 1 0 0
GP33 69 M AC 251 12.29 N/A 0 1 0 0 0 0 1
GP34 60 M AC T2N2M1b 491 12.36 CRT: ca/pa Before N/A 1 1 0 2 1 1 3
GP35 70 F SCC T4N0M0 1074 19.86 CRT: cis/et Before PMD 1 1 0 1 1 0 2
GP36 75 F AC T2aN3M0 521 13.34
CRT:
ca/pal Before PMR 1 2 2 1 1 0 1
GP37 78 M AC T2bN2M0 763 15.79 CRT: ca/pa Before CMR 1 1 2 2 2 0 2
GP38 68 F AC T3N2M1b 508 17.28 CRT: cis/et After N/A 1 1 0 1 1 1 2
GP39 75 M NSCLC T2bN3M0 913 19.81 CRT: ca/pa Before N/A 0 1 0 3 1 2 3
GP40 70 M AC T3N0M0 409 15.63 RT Before N/A 3 1 0 1 2 0 1
GP41 72 M NSCLC T1N2M0 399 16.55 CRT: ca/pa Before PMR 1 1 0 1 1 0 0
GP42 64 F AC N/A 17.39 N/A 1 1 0 0 0 0 0
GP43 67 M SCC T4N1M0 780 15.05 N/A 1 1 0 0 1 0 0
GP44 62 M NSCLC T1N2M0 415 15.36 CRT: ca/pa Before CMR 1 1 1 3 2 1 2
GP45 74 F AC T1bN3M0 718 17.10 CRT: ca/pa Before N/A 1 1 0 1 1 0 2
GP46 74 F AC T2N3M0 477 17.50 CRT: cis/et Before PMR 3 1 0 1 0 0 0
GP47 68 M SCC rT0N2M0 160 10.55 CRT: ca/pa After PMR 1 1 2 1 1 0 2
GP48 63 F AC T1N2M0 259 17.42 RT After CMR 2 1 2 2 1 0 0
GP49 74 M SCC T2aN0M0 129 8.54 RT Before PMD 2 1 0 1 2 0 1
GP50 78 F NSCLC T1N2M0 161 13.23 CRT: ca/pa Before CMR 1 2 2 1 1 1 1
GP51 82 M AC T1cM0M0 124 9.20 RT After PMD 2 1 0 1 1 0 0
GP52 48 M AC T3N2M0 338 13.86 CRT: cis/et After CMR 3 1 1 2 1 0 1
GP53 67 M SCC T1N0M0 118 15.20 CRT: cis/et Before CMR 2 2 2 1 2 0 2
GP54 68 F AC T1bN2M0 264 13.69 CRT: ca/pa After PMR 0 1 1 1 2 0 2
GP55 82 M SCC T2aN2M0 165 13.65 CRT: ca After CMR 0 0 0 1 1 1 0
GP56 48 M AC T3N2M0 502 15.04 CRT: ca/pa After PMR 1 1 0 1 1 0 1
GP57 68 M AC T3N0M0 221 12.71 CRT: ca/pa Before CMR 1 2 2 0 1 0 1
GP58 68 M AC T2aN2M0 537 16.97 CRT: ca/pa Before PMD 2 1 0 1 1 0 0
GP59 71 F SCC T4N0M0 208 11.22 CRT: ca/pa Before PMR 2 1 1 1 3 0 0
GP60 35 M AC T2bN2M1b 538 14.10 CRT: cis/et Before PMD 1 1 0 1 1 1 2
GP61 67 M NSCLC T3N2M0 804 17.45 CRT: ca/pa After CMR 2 1 1 0 1 0 1
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Table 4. Cont.
Patient
ID Age Gender Pathology Stage
PTV
(cm3) MLD RT/CRT
4 Weeks Beforeore
or After RT
PET
Response
Dyspnoea
Grade
Cough
Grade
Pneumonitis
Grade
Dermatitis
Grade
Fatigue
Grade
Nausea
Grade
Dysphagia
Grade
GP62 80 F AC T1N2M0 293 18.90 CRT: ca/pa After CMR 2 2 2 0 2 1 2
GP63 63 F SCC T3N2M0 619 16.43 CRT: ca/pa PMR 1 2 1 1 1 0 2
GP64 84 F SCC T4N0M0 91 5.90 RT After CMR 1 1 0 0 2 0 2
GP65 72 M AC T3N2M0 476 15.57 CRT: ca/pa Before PMR 0 2 1 1 1 0 0
GP66 71 M NSCLC T4N0M0 477 12.40 CRT: ca/pa After PMR 1 2 1 1 1 0 2
GP67 68 F AC T1aN1M0 267 14.45 RT Before PMD 2 1 2 1 1 0 2
GP68 80 M SCC T2BN2M0 281 12.59 CRT: ca/pa After CMR 2 2 1 1 1 0 1
GP69 71 M SCC T2N2M0 511 17.94 CRT: ca/pa After CMR 2 1 2 0 2 0 0
GP70 64 M AC T4N2M1b 820 15.00 CRT: ca/pa After N/A 1 1 0 0 1 2 1
Of the 45 patients recruited for the GalliPET VQ-RT clinical trial, 7 (data shaded grey) did not complete the full course of treatment due to disease progression (1 patient), changed to
palliative treatment due to the extent of disease (1 patient), or lacked a full γ-H2AX dataset due to logistic errors, sample loss or processing failures (6 patients). The complete datasets for
38 patients were, therefore, analyzed for this translational study; M—male, F—female, SCC—squamous cell carcinoma, NSCLC—non-small cell lung cancer, AC—adenocarcinoma,
ca/pa—carboplatin/paclitaxel, cis/et—cisplatin/etoposide, ca—carboplatin, N/A—not available.
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3. Discussion
Contemporary practice in thoracic radiation oncology involves initially prescribing the established
curative regime of 60–66 Gy in 30–33 fractions for all patients and planning the RT to determine if the
volume can be safely treated with the prescribed dose. A complex interaction between radiation-induced
damage to parenchymal cells, supporting vasculature and associated fibrotic reactions results in acute
and late radiation toxicities. In the lung, these changes can manifest in reduced pulmonary function
and in a chronic inflammatory cascade, which results in pneumonitis [21].
To date, the strongest predictors of radiation-induced lung injury are based on the volume of
normal lung tissue irradiated. These parameters (V20 and MLD) have been validated on meta-analysis
of multiple thoracic RT trials, and are often used as binary limits to select patients for the ability
to tolerate curative intent treatment with an acceptable toxicity profile [6]. There are, however,
a population of patients that experience significant toxicity without any clinical risk factors and with
acceptable RT dosimetric parameters. It has been hypothesised that such patients may have inherent
biological factors underlying their RS and that if detected with an assay before or early in course
of RT, their treatment plans could be adapted to reduce risk of toxicity. The ideal biomarker would
identify patients at higher risk of toxicity while also providing information on the likelihood of tumour
response to treatment. A biomarker, if validated, would enhance the informed consent process where
patients could be more accurately advised of the probability of developing treatment-related toxicity
and of tumour control for a given prescribed dose. This would foster engagement in the process of
planning and empower patients to have a greater say in their treatment.
A number of strategies have been proposed for such advances in personalized care in thoracic
radiation oncology. These include the use of functional lung imaging to identify and avoid regions
of working lung during the planning process, the use of early and mid-treatment cytokine levels to
identify patients at increased risk of lung toxicity and the use of novel biomarkers to predict toxicity
risk [11,22,23]. Previously, we have demonstrated that RT-related early changes in a panel of plasma
cytokines were associated with higher grades of radiation-induced lung toxicity [23]. Changes in
concentrations of IP-10, MCP-1, Eotaxin, IL-6 and TIMP-1 have also been associated with accumulation
of DNA damage in normal tissues outside of the irradiated volume during RT treatment for NSCLC [14].
In a retrospective case-study of a patient with severe clinical RS, our group demonstrated
inefficient repair of DNA damage, as assessed by the kinetics of the γ-H2AX response, in PBMC
and hair follicles, following ex vivo irradiation [24]. This led to a more comprehensive retrospective
study from which statistical criteria were proposed to define DNA repair deficiency [15,16]. However,
we have subsequently found that RT itself modulates the repair capacity [25]. Thus, we can anticipate
that the counterpart of the RS map published in our retrospective study [15], which would emerge
from a prospective study, would have modified scales. The qualitative features of the map would be
retained, e.g., the points for radiosensitive individuals would map the region in the top left-hand corner.
In this context, the RS map has been helpful in the current study. More generally, a large prospective
study will be required to refine our statistical criteria of severe clinical RS for the γ-H2AX-based
predictive assay.
The published prospective studies that utilized γ-H2AX as a predictive biomarker for both
acute and late normal tissue toxicity revealed mixed results. In clinical trials aiming to prospectively
identify head and neck cancer RT patients with a higher degree of radiation-induced mucositis,
Fleckenstein et al. [26] found a trend for delayed DSB repair. Similarly, Goutham et al. [27] and Li
et al. [28] successfully separated overresponding and non-overresponding patients based on post
irradiation γ-H2AX kinetics, and in one of these studies [27], also for residual foci. On the other hand,
in a number of clinical studies, the assay failed to predict RS in prospective and retrospective patient
cohorts, e.g., [29–31]. It is worthwhile to note that in some of the negative reports, the failure could be
ascribed to suboptimal study design and analysis. None of the clinical RS studies published to date
involve lung cancer RT patients. The GalliPET VQ-RT clinical trial that has been conducted at our
institute provided an opportunity to study real-time dynamics of DNA damage accumulation and
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resolution in PBMC of 38 NSCLC patients that were collected before, during and after RT treatment
and to associate the individual DDR with the patients’ clinical responses.
We found a substantial increase in the mean number of γ-H2AX foci in PBMC collected from
patients at 1 h post first RT session compared to pre-treatment values. We concluded that these foci were
induced by irradiation of cells while they were traveling within the RT treatment volume. The analysis
of foci frequency distributions based on the proposed model allowed calculation of the fraction of cells
subjected to irradiation and the average and excess foci number in these cells. The excess foci number
correlated with PTV, MLD and a combined PTV/MLD parameter. This study indicated that irradiation
of blood in both tumour and normal lung tissue is a source of DNA damage in PBMC. The numbers of
induced foci obtained from experimental distributions exceeds those predicted from calculation based
on RT treatment parameters, indicating that potentially substantial DNA damage may emerge from
irradiation of other than lung normal tissues that are located within the irradiation beam.
An increased mean foci number was also observed in PBMC collected 4 weeks into RT. Given
treatment logistics necessitated that some 4-week samples were collected before RT treatment and
some were collected after RT treatment; we analyzed these two subgroups separately. A substantial
and statistically significant increase of the mean foci number was found in samples collected after RT
treatment, supporting the interpretation that irradiation of cells within the treatment volume accounts
for these foci. A smaller, yet still statistically significant, increase of the mean foci number was also
found in the subgroup of samples collected before the RT fraction in the 4-week group. This could be
explained by induction of DNA damage by systemic (abscopal) effects in susceptible progenitor cells
that is revealed later as increased unrepaired damage in PMBC [17,32].
In the study of ex vivo 2 Gy-irradiated PBMC, we considered the unrepairable component Q,
the value derived from the nonlinear regression analysis of post irradiation foci kinetics, as an indicator
of the efficiency of DNA repair and a predictor of radiotoxicity [15]. We found no obvious outliers
in a set of Q-values, therefore, no patients predicted to have severe RS were revealed. In parallel
with this finding, there were no unusually severe clinical toxicities in the patient cohort. However,
evidence from preclinical and clinical observations suggests that normal tissue toxicity is multifactorial,
dynamic and progressive process [33–35]. Accordingly, in subgroups of patients with various grades of
radiotoxicity, we found a correlation between Q-values and the toxicity grade for cough and dysphagia.
Q-values and the position in the 2-D RS map were in the high RS zone for three patients with the
highest combined cough and dysphagia grade. These patients also demonstrated other types of toxicity
and had persistent health problems that required clinical intervention. They demonstrated a complete
metabolic response, suggesting that their tumours were also sensitive to radiation.
We also considered the ratio of the mean foci number in samples collected 24 and 1 h after the
first RT session, which reflects the in vivo repair of DNA damage induced by RT. We found a good
concordance of this ratio with Q-values (Figure 4). Indeed, the three patients with high grade of
cough/dysphagia had higher than average ratio values, further supporting this concordance. Despite
this trend, however, the ratio is not as accurate as Q-value, hence no statistically significant correlation
between patient subgroups with different levels of toxicities was found, except for the trend of the
increased ratio with the increased combined cough and dysphagia toxicity (similar to the foci numbers
in PBMC collected at 24 h post first RT session). These values are simpler parameters than the in vitro
Q-value and can be used as a triage, to reveal patients that are potential candidates for the more precise
ex vivo irradiation test. Their accuracy could be improved by increasing the number of analyzed cells
and by standardizing immunostaining/microscopy protocols to achieve high image reproducibility.
4. Materials and Methods
4.1. Patient Recruitment
Patients with NSCLC (n = 45) were recruited for the GalliPET VQ-RT clinical trial (ethics approval
from the Peter MacCallum Cancer Centre; Universal Trial Number U1111-1138-4421, date of approval
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7 July 2014). The patients were aged between 49 and 82 years (the median age was 68); 30 males and
15 females. A total dose of 60 Gy was delivered to all patients in 30 fractions over 6 weeks using a 3D
conformal technique. Six patients received RT only; 39 received RT with concurrent chemotherapy. All
patients gave written informed consent for participation in this trial. Patient information is presented
in Table 4. Toxicities were recorded using Common Terminology Criteria for Adverse Events (CTCAE)
v4.0. We did not assume that the gallium-68 perfusion protocol with the whole-body radiation dose of
the PET scan ~50 mSv could interfere with the results of the study. The impact was controlled as all
patients were exposed to the GalliPET protocol.
4.2. Blood Collection and Processing
Blood samples from 43 patients were analysed. Of the 45 recruited trial patients, 7 did not
complete the full course of treatment (due to disease progression), changed to palliative treatment
due to the extent of disease or lacked a full γ-H2AX dataset due to sample loss or processing failures.
A complete dataset with a full complement of translational biomarker time points was, therefore,
available for 38 patients.
The logistic of the study is presented in Figure 1. Venous blood (15 mL) was collected in
ethylenediaminetetraacetic acid (EDTA) tubes at each time point: pre-treatment (baseline), 1 h after
the first RT fraction, approximately 24 h after the first RT fraction (just before the second fraction),
4 weeks into the treatment course (before or after RT fraction) and 3 months after the final RT treatment
(at the follow-up appointment). The protocol for blood processing has been described previously,
i.e., [15]. As soon as possible after blood collection, PBMC were separated by centrifugation over
Ficoll-Paque PLUS (GE Healthcare Life Sciences, Sheffeld, UK) at 600× g for 45 min (without brakes)
and washed in the in-house phosphate buffered saline (PBS). Aliquots of isolated PBMC were fixed
immediately post blood collection and also aliquots of the majority of PBMC samples were fixed at
24 h post blood collection.
Aliquots of PBMC from all baseline samples were incubated for 30 min at 37 ◦C in RPMI-1640
medium supplemented with 10% foetal bovine serum (Gibco Life Technologies, Mulgrave, VIC,
Australia) and 0.1% gentamicin (Pfizer, Sydney, NSW, Australia). PBMC were then transferred into
15 mL tubes filled with fresh warm complete medium and irradiated to a dose of 2 Gy. Due to
relocation of the research laboratory, initially a 137caesium source (GammaCell 40 Irradiator, Nordion
International, Kanata, ON, Canada) at a dose-rate of 0.53 Gy/min, and later X-rays (X-RAD320 Irradiator,
Precision X-ray, North Branford, CT, USA) at a dose-rate of 1.15 Gy/min, were used for irradiations. The
two radiation sources were compared with respect to the γ-H2AX response in ex vivo 2-Gy irradiated
PBMC. Fricke dosimetry was used in the comparison studies. The cells were then transferred to 25 cm
2-tissue culture flasks, incubated at 37 ◦C in 5% CO2 in air, sampled at 1, 3, 6, and 24 h post irradiation,
fixed in 4% paraformaldehyde, washed in PBS and stored in 70% ethanol at −20 ◦C.
In addition, PBMC from all collected samples including baseline that were not exposed to ex vivo
irradiation were fixed immediately after blood collection, and, when it was logistically possible, other
aliquots were incubated overnight in the complete medium and subsequently fixed at 24 h postblood
collection. All PBMC samples were stored in 70% ethanol at −20 ◦C until immunostaining.
4.3. Immunostaining, Microscopy and Image Analysis
PBMC were cytospun onto microscope slides (Menzel-Glaser Lomb, Braunscheig, Germany) using
a Cytospin 4 cytocentrifuge (Thermo-Scientific, Waltham, MA, USA) for 4 min at 800× g. The cell spots
were dried for 10 min, outlined with a PAP pen (ProSciTech, Kirwan, QLD, Australia) and blocked
with 8% BSA (Sigma-Aldrich, St Louis, MO, USA) for 30 min prior to immunostaining. The slides
were incubated with a mouse monoclonal anti-γ-H2AX antibody (Abcam, Cambridge, UK, 1:500) in a
humidified chamber at room temperature for 2 h, then after washing, cells with PBS were incubated
with Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody (Invitrogen, Mulgrave,
VIC, Australia, 1:500) for 1 h. Primary and secondary antibodies were diluted into 1% BSA in PBS-TT
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(PBS containing 0.5% Tween-20 and 0.1% Triton X-100, Sigma-Aldrich, St Louis, MO, USA). Slides
were washed three times with PBS and mounted in 4′,6′-diamidino-2-phenylindole (DAPI)-containing
Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA).
Microscopy was performed with an Olympus FV1000 laser confocal scanning microscope
(Olympus, Tokyo, Japan). Serial optical sections were used to create a single maximum projection
image for each field; these images contained all detected γ-H2AX foci throughout the nuclear volume.
A minimum of 3 fields were analysed for each time/dose point; usually sufficient to count foci in at
least 100 cells. The nuclei of mononuclear cells were identified, and γ-H2AX foci within these nuclei
were counted automatically using the in-house developed software JQuantPro v2.0 [36,37].
4.4. Data Analysis
4.4.1. Distributions of Foci Numbers
We analysed foci frequency distribution for the sole purpose of evaluating the fraction of irradiated
cells and the average number of radiation-induced foci in these cells. Distributions of foci frequencies
in untreated PBMC from samples collected at 1 h post first fraction of RT were approximated by least
squares regression using the following expression for the probability of a cell to have k foci:
Pk(λ,α, β, f ) = (1− f )PPk (λ) + f
k∑
i=0
PPi (a)Gk−i(α, β) (1)
which assumes that γ-H2AX foci originate from two sources, randomly distributed background foci
and foci that are induced by irradiation in PBMC, which are located within the irradiation volume
in the course of RT. The parameter f denotes the fraction of PBMC that are subject to irradiation.
The count of background foci is assumed to follow a Poisson distribution with average value of λ:
PPk (λ) = e
−λλ
k
k!
(2)
and the number of radiation-induced foci are assumed to follow a gamma distribution with parameters
α and β:
Gk(α, β) =
β∝
Γ(α)
kα−1e−βk (3)
The purpose of least squares regression is to evaluate the fraction of irradiated PBMC (f ) and
the average number of induced foci in these cells (calculated as the ratio α/β). Gamma distribution is
chosen as an empirical model suitable for the description of the distribution of foci in cells following
irradiation with a range of doses without any implied biological background.
4.4.2. Analysis of Foci Kinetics
For the analysis ofγ-H2AX kinetics in PBMC irradiated ex vivo with 2 Gy X-rays, we first calculated
the modal average foci number values for each time point t (denoted below as N(t)) by applying least
squares regression according to Equation (2) to the experimental foci frequency distributions. As we
demonstrated previously, the Poisson modal parameter estimate provides a better description of the
count of radiation-induced foci than an arithmetic mean. The kinetics of foci elimination was analysed
using a least square with a model that assumes the exponential repair of DSB with a rate R and the
presence of irreparable component Q as unknown parameters, according to the following equation:
N(t) = Nm
(
(1−Q)e−Rt + Q
)
(4)
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4.5. Statistical Analysis
Paired or unpaired t-tests were used for the comparison of patient foci numbers between groups.
For correlation studies, we used Pearson product moment correlation (correlation coefficient r and
corresponding p-value).
5. Conclusions
This study provided novel information on the clinical utility of the γ-H2AX assay to monitor
DDR in a clinical setting. Our earlier retrospective studies [15,16] provided a starting point towards
the objective of developing an assay to prospectively identify radiosensitive patients using the
γ-H2AX-based assay to assess the efficiency of their DNA repair. The current study of 38 patients
provided valuable information. The three NSCLC patients who scored highly on the assay could not
be described as extremely radiosensitive, at least in the time-frame of 36 months between treatment
and the present time. However, as survival in locally advanced NSCLC is poor, long-term survivorship
and development of very late toxicities are rare. Based on our results, in a large prospective trial,
we can expect that the number of patients with clinically proven normal tissue toxicities would be
less than the number found to have compromised DNA repair, indicating the requirement for a more
sophisticated approach to predict RS. This could be achieved by combining theγ-H2AX assay with other
functional assays that showed a predictive potential, such as initial DNA damage assessment, e.g., ATM
nucleo-shuttling [38], radiation-induced lymphocyte apoptosis (RILA) assay [39], or chromosome
aberrations [40]. Nevertheless, the detection of compromised DNA repair in the three patients showing
modest clinical RS, and requiring special follow-up, raises the possibility of prospective identification
of modestly radiosensitive patients that could be of clinical benefit.
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